论文部分内容阅读
目的：了解肺癌患者血清自身抗体阳性率、细胞内定位及荧光图形特点，探索自身抗体作为肿瘤标志物的可能性。方法：应用间接免疫荧光法（ｉｎｄｉｒｅｃｔ ｉｍｍｕｎｏｆｌｕｏｒｅｓｃｅｎｃｅ，ＩＩＦ）检测 ７７份肺癌以及 １４０份不同年龄段正常人血清中自身抗体。提取人喉癌上皮细胞（Ｈｅｐ－２）蛋白抗原，采用蛋白质印迹法对８１份肺癌患者及５２份正常人血清进行分析。结果：肺癌组和对照组的自身抗体阳性率有显著差别，两组人群的自身抗体阳性率皆随年龄增长而增高（Ｐ＜０．０５），在不同年龄段，肺癌组皆显著高于对照组（Ｐ＜０．０１）。肺癌组和对照组在自身抗体荧光图形、靶抗原细胞内定位上均有明显不同。７４份肺癌患者血清中检测到阳性条带（７４／８１，９１．４％），显著高于对照组（３１／５２，６１．５％），其中大多数与自身免疫性疾病中常见的自身抗体不同，并发现８２．７％（６７／８１）的肺癌患者具有针对相对分子质量初步鉴定为６．５万的靶抗原的阳性条带，该条带仅在２２．２％（１２／５２）的正常人中查及。结论：肺癌患者血清的自身抗体谱与正常人生理性自身抗体谱及自身免疫性疾病中的自身抗体谱不同，进一步研究其靶抗原本质及其生物学意义，有助于深入认识肺
Objective: To understand the serum autoantibody positive rate, intracellular localization and fluorescence pattern characteristics of patients with lung cancer, and to explore the possibility of autoantibodies as tumor markers. METHODS: Indirect immunofluorescence (IIF) was used to detect autoantibodies in 77 lung cancers and 140 healthy people in different age groups. Human laryngeal carcinoma epithelial cell (Hep-2) protein antigen was extracted and Western blot was used to analyze 81 patients with lung cancer and 52 normal controls. Results: There was a significant difference in autoantibody positive rate between lung cancer group and control group. The positive rate of autoantibodies in both groups increased with age (P<0.05). In different age groups, the lung cancer group was significantly higher than the control group. Group (P < 0.01). The lung cancer group and the control group were significantly different in the autoantibody fluorescence pattern and the intracellular localization of the target antigen. Positive bands were detected in the serum of 74 lung cancer patients (74/81, 91.4%), significantly higher than those in the control group (31/52, 61.5%), most of which were common with autoimmune diseases. Different antibodies and found that 82.7% (67/81) of lung cancer patients had a positive band with a target antigen that was initially identified with a relative molecular mass of 65,000, and the band was only at 22.2% (12/52) ) Check out the normal people. Conclusion: The autoantibody spectrum of serum from patients with lung cancer is different from the normal autologous antibody spectrum and the autoantibody spectrum in autoimmune diseases. Further research on the nature of the target antigen and its biological significance will help to understand the lungs in depth.